Melanoma, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 35-1 - November 18, 2020
Editor: F. Stephen Hodi
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 4 8 3 - 4
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 4 8 4 - 1

This issue of Hematology/Oncology Clinics, Guest Edited by F. Stephen Hodi, is devoted to Melanoma. This issue is one of six selected each year by our series Consulting Editors,… Read more

Melanoma, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Hematology/Oncology Clinics, Guest Edited by F. Stephen Hodi, is devoted to Melanoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: State of Melanoma, Biology of Melanoma, Epidemiology of Melanoma, Surgical Management of Melanoma, Melanoma Adjuvant Therapy, Targeted Therapies for Melanoma, Non-cutaneous Melanomas, Immune Checkpoint Therapies for Melanoma, Resistance Mechanisms to Current Therapies, Cellular Therapy and Cytokine Treatments for Melanoma, Combinatorial Approaches to the Treatment of Melanoma, and Melanoma Future Directions.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
State of Melanoma: An Historic Overview of a Field in Transition
Key points
Introduction/history
Evolution of surgical therapy
Lymph node evaluation and management
Evolution of medical therapy
1970 to 1990: the era of chemotherapy
1990 to 2010: the era of interferon and IL-2
2010 to 2020: the era of immune checkpoint blockade and targeted therapy
Discussion and future directions
Clinics care points
Biology of Melanoma
Key points
Introduction
From melanocyte to melanoma
Molecular signaling in melanoma
Biology of therapy resistance in melanoma
Summary
Epidemiology of Melanoma
Key points
Introduction
Melanoma incidence and mortality rates
Melanoma across the world
Risk factors
Host factors
Environmental risk factors
Screening for melanoma
Adjuvant Therapy of Melanoma
Key points
Introduction
Adjuvant therapy with interferon alpha
Adjuvant biochemotherapy
Adjuvant immunotherapy with vaccines
Adjuvant therapy with bevacizumab
Adjuvant therapy with ipilimumab
North American intergroup E1609
Adjuvant therapy with anti-PD-1 antibodies
Adjuvant targeted therapy with dabrafenib and trametinib
Adjuvant radiation therapy
Discussion
Summary
Extracutaneous Melanoma
Key points
Introduction
Mucosal melanoma
Therapeutic options
Uveal melanoma
Summary
Clinics care points
Immune Checkpoint Therapies for Melanoma
Key points
Introduction
Immune checkpoint inhibition
Cytotoxic T-lymphocyte–associated protein 4 inhibition (ipilimumab)
Programmed cell death protein 1 inhibition (nivolumab and pembrolizumab)
Combination immune checkpoint inhibition (ipilimumab/nivolumab)
Adjuvant melanoma immunotherapy
Neoadjuvant melanoma immunotherapy
Other immune checkpoint inhibitor combinations and future directions
Summary
Clinics care points
Advanced Melanoma: Resistance Mechanisms to Current Therapies
Key points
Introduction
Discussion
Summary
Clinics care points
Cellular Therapy and Cytokine Treatments for Melanoma
Key points
Introduction
Summary
Clinics care points
Combinatorial Approaches to the Treatment of Advanced Melanoma
Key points
Introduction
First-line monotherapy regimens in melanoma as a background to understanding efficacy of combinations
Combinatorial approaches in advanced melanoma
Combinations of immunotherapy and mitogen-activated protein kinase pathway targeted therapy
Other immunotherapy combinations
Discussion and Summary
Clinics care points